Research Trials
Shaping the Future of Neurology—Together.
Premier Neurology has been leading neurological research in the Upstate, SC area since 2017
Due to the extensive research experience of Dr. Mary Hughes, Premier Neurology is the only practice in South Carolina involved in many critical neurological research trials. Dr. Hughes has been closely involved in groundbreaking neurological research, leading to new FDA approvals for medications like subcutaneous Ocrevus®.
We pride ourselves on being able to offer our patients cutting-edge options for treatments and care. By opening the opportunity to participate in research trials, our patients can contribute to medical advancements while receiving close monitoring and early access to promising new treatments.
Benefits of Participating in a Research Trial
- Early access to pioneering treatments not yet publically available
- Focused medical support and monitoring from our clinical Research Team
- Contribute to the development of new therapies for others living with neurological conditions
- Participation in trials alleviates the cost of disease management as many trials cover the cost of medications and care
Current Research Trials
Explore our current research trials to determine if you would be a good candidate to participate. If you are interested in learning more about our research opportunities, please contact our Research Team at 864-655-0880 or send us a message below.
Reshape: A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib. (LEARN MORE)
Enhance C: Evaluating efficacy when transitioning from a current Disease Modifying Therapy (DMT) to ublituximab. (LEARN MORE)
Remaster: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis. (LEARN MORE)
Monarch: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis. (LEARN MORE)
Primrose: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis. (LEARN MORE)
LTS: An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis.
COMB: An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis.
Remodel: A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib.
Frexalt: Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis.
Menstrual Migraine: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension.
Interested in joining a research trial?
Send the Premier Neurology Research Team a message and we will be in contact soon.